Airway Medix S.A. focuses on research and development work and commercialisation of innovative, disposable devices for the mechanically ventilated patients in the Intensive Care Units (ICU), and for the patients in life-threatening conditions in the anaesthesiology departments.
The family of products developed by Airway Medix is aimed at limiting the growth of a biofilm in patients, reducing the microbial flora in the oral cavity and improving the fitting and tightness of intubation tubes. By reducing biofilm formation and preventing entry of infected material into the lungs, the products protect patients from acquiring Ventilation Associated Pneumonia (VAP).
Ventilation Associated Pneumonia is considered one of the most serious and most costly hospital-acquired infections.
Gen. Zajączka 11/14, 01-510 Warszawa – Poland
Dec. 1, 2014Stock exchange(s)
Warsaw Stock Exchange
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.